NCT05049252View on ClinicalTrials.gov

Biomarkers Predictive for Cervical Intraepithelial Neoplasia Grade 2 (CIN2) Evolvement

UnknownOBSERVATIONAL
Enrollment

500

Participants

Timeline

Start Date

June 1, 2020

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2023

Conditions
Cervical Intraepithelial Neoplasia Grade 2 (CIN2)
Trial Locations (1)

7400

Department of Gynecology and Obstetrics, Herning Regional Hospital, Herning

Sponsors

Collaborators (1)

DDL Diagnostic Laboratory
All Listed Sponsors
collaborator

University of Southern Denmark

OTHER

collaborator

DDL Diagnostic Laboratory

UNKNOWN

collaborator

University of Cambridge

OTHER

collaborator

National Cancer Institute (NCI)

NIH

collaborator

University of Virginia

OTHER

lead

University of Aarhus

OTHER

NCT05049252 - Biomarkers Predictive for Cervical Intraepithelial Neoplasia Grade 2 (CIN2) Evolvement | Biotech Hunter | Biotech Hunter